TW201402121A - 包含１－（６－｛［６－（４－氟苯基）［１，２，４］三唑并［４，３－ｂ］嗒□－３－基］硫基｝－１，３－苯并噻唑－２－基）－３－（２－嗎啉－４－基乙基）尿素化合物之抗腫瘤組合物 - Google Patents
包含１－（６－｛［６－（４－氟苯基）［１，２，４］三唑并［４，３－ｂ］嗒□－３－基］硫基｝－１，３－苯并噻唑－２－基）－３－（２－嗎啉－４－基乙基）尿素化合物之抗腫瘤組合物 Download PDFInfo
- Publication number
- TW201402121A TW201402121A TW102124952A TW102124952A TW201402121A TW 201402121 A TW201402121 A TW 201402121A TW 102124952 A TW102124952 A TW 102124952A TW 102124952 A TW102124952 A TW 102124952A TW 201402121 A TW201402121 A TW 201402121A
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- compound
- aqueous liquid
- dose
- liquid pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305840 | 2012-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201402121A true TW201402121A (zh) | 2014-01-16 |
Family
ID=48782350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102124952A TW201402121A (zh) | 2012-07-12 | 2013-07-11 | 包含１－（６－｛［６－（４－氟苯基）［１，２，４］三唑并［４，３－ｂ］嗒□－３－基］硫基｝－１，３－苯并噻唑－２－基）－３－（２－嗎啉－４－基乙基）尿素化合物之抗腫瘤組合物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20150119391A1 (es) |
| EP (1) | EP2872119A1 (es) |
| JP (1) | JP2015525754A (es) |
| KR (1) | KR20150030761A (es) |
| CN (1) | CN104470500A (es) |
| AR (1) | AR091727A1 (es) |
| AU (1) | AU2013288676A1 (es) |
| BR (1) | BR112015000497A2 (es) |
| CA (1) | CA2878500A1 (es) |
| CL (1) | CL2015000074A1 (es) |
| CO (1) | CO7160069A2 (es) |
| CR (1) | CR20150005A (es) |
| EA (1) | EA201590199A1 (es) |
| HK (1) | HK1209642A1 (es) |
| IL (1) | IL236662A0 (es) |
| IN (1) | IN2015KN00075A (es) |
| MA (1) | MA37753B1 (es) |
| MX (1) | MX2015000532A (es) |
| PH (1) | PH12015500060A1 (es) |
| SG (1) | SG11201500123XA (es) |
| TN (1) | TN2015000011A1 (es) |
| TW (1) | TW201402121A (es) |
| UY (1) | UY34909A (es) |
| WO (1) | WO2014009500A1 (es) |
| ZA (1) | ZA201500129B (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711643D0 (en) * | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| FR2817750B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Composition pharmaceutique de dronedarone pour administration parenterale |
| DK1594434T3 (da) * | 2003-01-14 | 2017-01-02 | Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science | Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| US20100331357A1 (en) * | 2008-02-28 | 2010-12-30 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
| CN101444510B (zh) * | 2008-12-31 | 2011-03-09 | 南京卡文迪许生物工程技术有限公司 | 含有伏立康唑的药物制剂及其制备方法 |
| FR2941951B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
-
2013
- 2013-07-11 MA MA37753A patent/MA37753B1/fr unknown
- 2013-07-11 BR BR112015000497A patent/BR112015000497A2/pt not_active IP Right Cessation
- 2013-07-11 AR ARP130102458 patent/AR091727A1/es unknown
- 2013-07-11 IN IN75KON2015 patent/IN2015KN00075A/en unknown
- 2013-07-11 WO PCT/EP2013/064741 patent/WO2014009500A1/en active Application Filing
- 2013-07-11 EP EP13735312.4A patent/EP2872119A1/en not_active Withdrawn
- 2013-07-11 CN CN201380037070.8A patent/CN104470500A/zh active Pending
- 2013-07-11 AU AU2013288676A patent/AU2013288676A1/en not_active Abandoned
- 2013-07-11 EA EA201590199A patent/EA201590199A1/ru unknown
- 2013-07-11 JP JP2015521001A patent/JP2015525754A/ja active Pending
- 2013-07-11 CA CA 2878500 patent/CA2878500A1/en not_active Abandoned
- 2013-07-11 KR KR20157003404A patent/KR20150030761A/ko not_active Application Discontinuation
- 2013-07-11 TW TW102124952A patent/TW201402121A/zh unknown
- 2013-07-11 SG SG11201500123XA patent/SG11201500123XA/en unknown
- 2013-07-11 MX MX2015000532A patent/MX2015000532A/es unknown
- 2013-07-12 UY UY34909A patent/UY34909A/es not_active Application Discontinuation
-
2015
- 2015-01-07 CR CR20150005A patent/CR20150005A/es unknown
- 2015-01-08 TN TNP2015000011A patent/TN2015000011A1/fr unknown
- 2015-01-08 CO CO15004112A patent/CO7160069A2/es unknown
- 2015-01-08 ZA ZA2015/00129A patent/ZA201500129B/en unknown
- 2015-01-09 US US14/593,059 patent/US20150119391A1/en not_active Abandoned
- 2015-01-09 CL CL2015000074A patent/CL2015000074A1/es unknown
- 2015-01-09 PH PH12015500060A patent/PH12015500060A1/en unknown
- 2015-01-11 IL IL236662A patent/IL236662A0/en unknown
- 2015-10-26 HK HK15110497.0A patent/HK1209642A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TN2015000011A1 (en) | 2016-06-29 |
| BR112015000497A2 (pt) | 2017-06-27 |
| IN2015KN00075A (es) | 2015-07-31 |
| MA37753B1 (fr) | 2019-04-30 |
| CA2878500A1 (en) | 2014-01-16 |
| HK1209642A1 (en) | 2016-04-08 |
| AR091727A1 (es) | 2015-02-25 |
| MX2015000532A (es) | 2015-05-15 |
| UY34909A (es) | 2013-11-29 |
| EA201590199A1 (ru) | 2015-05-29 |
| CL2015000074A1 (es) | 2015-06-12 |
| CO7160069A2 (es) | 2015-01-15 |
| ZA201500129B (en) | 2015-12-23 |
| WO2014009500A1 (en) | 2014-01-16 |
| MA37753A3 (fr) | 2018-05-31 |
| PH12015500060A1 (en) | 2015-03-02 |
| KR20150030761A (ko) | 2015-03-20 |
| JP2015525754A (ja) | 2015-09-07 |
| AU2013288676A1 (en) | 2015-02-05 |
| MA37753A2 (fr) | 2016-06-30 |
| CR20150005A (es) | 2015-04-06 |
| SG11201500123XA (en) | 2015-02-27 |
| IL236662A0 (en) | 2015-02-26 |
| CN104470500A (zh) | 2015-03-25 |
| US20150119391A1 (en) | 2015-04-30 |
| EP2872119A1 (en) | 2015-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5449784B2 (ja) | 抗癌用途のためのドキソルビシン製剤 | |
| JP6695003B2 (ja) | 癌のための併用療法 | |
| CN105338973A (zh) | 使用辅酶q10联合疗法治疗癌症 | |
| CN107257806A (zh) | 用于治疗pvns的抗csf1r抗体 | |
| US11795217B2 (en) | Interleukin-1 inhibition for combination treatment of pancreatic cancer cachexia | |
| US20230181534A1 (en) | Use of a proteasome inhibitor for the treatment of central nervous system (cns) cancers | |
| KR20220113699A (ko) | 나노입자 조성물에 대한 바이오마커 | |
| CN105764515A (zh) | 对胰腺癌的治疗 | |
| Quintero Aldana et al. | First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial | |
| TW201402121A (zh) | 包含１－（６－｛［６－（４－氟苯基）［１，２，４］三唑并［４，３－ｂ］嗒□－３－基］硫基｝－１，３－苯并噻唑－２－基）－３－（２－嗎啉－４－基乙基）尿素化合物之抗腫瘤組合物 | |
| JP2023524872A (ja) | がんの治療のためのａｔｒ阻害剤 | |
| CN106714795A (zh) | 用于治疗尤因家族肿瘤的组合物及方法 | |
| EP3389660B1 (en) | Combination therapy for cancer | |
| US20210121475A1 (en) | Imipramine compositions and methods of treating cancer | |
| KR20150003786A (ko) | Pi3k 저해제 및 mek 저해제를 이용한 암 치료 방법 | |
| US20230321102A1 (en) | TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077 | |
| WO2022247846A1 (zh) | 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途 | |
| CN117580572A (zh) | 用安森司坦和帕博西尼治疗乳腺癌 | |
| TW201542201A (zh) | 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）於具有轉移性ｎｓｃｌｃ發展病患中經多西紫杉醇為基礎治療之後的用途 | |
| CN116265015A (zh) | 多西他赛白蛋白组合物与vegf抑制剂或vegfr抑制剂的组合及其用途 | |
| KR20210097139A (ko) | 데비미스타트를 사용하는 급성 골수성 백혈병을 치료하기 위한 치료적 방법 및 조성물 | |
| Ismail et al. | Bevacizumab plus FOLFIRI as first line therapy for Metastatic Colorectal Cancer | |
| AU2017268356A1 (en) | Combination therapies using indazolylbenzamide derivatives for the treatment of cancer | |
| WO2015104417A1 (en) | Use of cabazitaxel for the treatment of gastric adenocarcinoma | |
| CN104784187A (zh) | 卡巴他赛的新颖抗肿瘤用途 |